Cargando…

Cell proliferation inhibitors and apoptosis promoters

Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of the apoptosis pathway. Ovarian cancer is an entity in which...

Descripción completa

Detalles Bibliográficos
Autor principal: Perez-Fidalgo, J. Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573461/
https://www.ncbi.nlm.nih.gov/pubmed/33240445
http://dx.doi.org/10.1016/j.ejcsup.2019.09.002
_version_ 1783597444659937280
author Perez-Fidalgo, J. Alejandro
author_facet Perez-Fidalgo, J. Alejandro
author_sort Perez-Fidalgo, J. Alejandro
collection PubMed
description Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of the apoptosis pathway. Ovarian cancer is an entity in which cell-cycle alterations are common. P53, a key regulator of checkpoint G1, is frequently altered in high-grade serous ovarian cancer. Targeting cell-cycle regulators will lead to mitotic catastrophe and cell death in these tumours. Promoting apoptosis is another target that is gaining interest in ovarian cancer. In this review, the most relevant evidence of clinical studies in ovarian cancer with compounds targeting cell cycle or promoting apoptosis is summarised.
format Online
Article
Text
id pubmed-7573461
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75734612020-11-24 Cell proliferation inhibitors and apoptosis promoters Perez-Fidalgo, J. Alejandro EJC Suppl Article Cancer is characterised by uncontrolled proliferation and prolonged cell survival. In some cases, tumour formation is the result from aberrant activity of various cell-cycle regulators leading to chromosome instability or from alteration of the apoptosis pathway. Ovarian cancer is an entity in which cell-cycle alterations are common. P53, a key regulator of checkpoint G1, is frequently altered in high-grade serous ovarian cancer. Targeting cell-cycle regulators will lead to mitotic catastrophe and cell death in these tumours. Promoting apoptosis is another target that is gaining interest in ovarian cancer. In this review, the most relevant evidence of clinical studies in ovarian cancer with compounds targeting cell cycle or promoting apoptosis is summarised. Elsevier 2020-08-22 /pmc/articles/PMC7573461/ /pubmed/33240445 http://dx.doi.org/10.1016/j.ejcsup.2019.09.002 Text en © 2020 Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Perez-Fidalgo, J. Alejandro
Cell proliferation inhibitors and apoptosis promoters
title Cell proliferation inhibitors and apoptosis promoters
title_full Cell proliferation inhibitors and apoptosis promoters
title_fullStr Cell proliferation inhibitors and apoptosis promoters
title_full_unstemmed Cell proliferation inhibitors and apoptosis promoters
title_short Cell proliferation inhibitors and apoptosis promoters
title_sort cell proliferation inhibitors and apoptosis promoters
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573461/
https://www.ncbi.nlm.nih.gov/pubmed/33240445
http://dx.doi.org/10.1016/j.ejcsup.2019.09.002
work_keys_str_mv AT perezfidalgojalejandro cellproliferationinhibitorsandapoptosispromoters